Loading...
•
Dec 31, 2021
Madrigal Q4 2021 Earnings Report
Madrigal reported its Q4 and full year 2021 financial results and provided business and clinical updates.
Key Takeaways
Madrigal Pharmaceuticals reported cash, cash equivalents and marketable securities of $270.3 million. Operating expenses were $64.6 million. Research and development expenses were $52.9 million and general and administrative expenses were $11.7 million.
Phase 3 MAESTRO-NAFLD-1 safety study achieved primary and key secondary endpoints, demonstrating resmetirom's safety and tolerability.
MAESTRO-NAFLD-1 study showed significant reductions in liver fat and atherogenic lipids with resmetirom treatment.
Topline results from the Phase 3 MAESTRO-NASH liver biopsy study are expected in Q4 2022.
Dominic F. Labriola, PhD, joined Madrigal as Chief Data and Analytics Officer, and Sunil Kadam, PhD, joined as Senior Vice President of Global Regulatory Affairs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...